These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34269904)

  • 1. WEE1 Inhibitor: Clinical Development.
    Kong A; Mehanna H
    Curr Oncol Rep; 2021 Jul; 23(9):107. PubMed ID: 34269904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of WEE1 Is Effective in
    Seligmann JF; Fisher DJ; Brown LC; Adams RA; Graham J; Quirke P; Richman SD; Butler R; Domingo E; Blake A; Yates E; Braun M; Collinson F; Jones R; Brown E; de Winton E; Humphrey TC; Parmar M; Kaplan R; Wilson RH; Seymour M; Maughan TS;
    J Clin Oncol; 2021 Nov; 39(33):3705-3715. PubMed ID: 34538072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
    Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
    Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
    Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
    Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the
    Kong A; Good J; Kirkham A; Savage J; Mant R; Llewellyn L; Parish J; Spruce R; Forster M; Schipani S; Harrington K; Sacco J; Murray P; Middleton G; Yap C; Mehanna H
    BMJ Open; 2020 Mar; 10(3):e033009. PubMed ID: 32184305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.
    Takebe N; Naqash AR; O'Sullivan Coyne G; Kummar S; Do K; Bruns A; Juwara L; Zlott J; Rubinstein L; Piekarz R; Sharon E; Streicher H; Mittra A; Miller SB; Ji J; Wilsker D; Kinders RJ; Parchment RE; Chen L; Chang TC; Das B; Mugundu G; Doroshow JH; Chen AP
    Clin Cancer Res; 2021 Jul; 27(14):3834-3844. PubMed ID: 33863809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
    Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
    Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
    Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
    Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway.
    Guo E; Xiao R; Wu Y; Lu F; Liu C; Yang B; Li X; Fu Y; Wang Z; Li Y; Huang Y; Li F; Wu X; You L; Qin T; Lu Y; Huang X; Ma D; Mills GB; Sun C; Chen G
    J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34825915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
    Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
    Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine.
    Moreira DC; Venkataraman S; Subramanian A; Desisto J; Balakrishnan I; Prince E; Pierce A; Griesinger A; Green A; Eberhardt CG; Foreman NK; Vibhakar R
    J Neurooncol; 2020 May; 147(3):531-545. PubMed ID: 32180106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.
    Fu S; Wang Y; Keyomarsi K; Meric-Bernstam F; Meric-Bernstein F
    Expert Opin Investig Drugs; 2018 Sep; 27(9):741-751. PubMed ID: 30102076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells.
    Li C; Shen Q; Zhang P; Wang T; Liu W; Li R; Ma X; Zeng X; Yin Y; Tao K
    J Exp Clin Cancer Res; 2021 Oct; 40(1):315. PubMed ID: 34625086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
    Ghelli Luserna di Rorà A; Cerchione C; Martinelli G; Simonetti G
    J Hematol Oncol; 2020 Sep; 13(1):126. PubMed ID: 32958072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
    Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM
    Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving treatment paradigms for platinum-resistant ovarian cancer: An update narrative review.
    Lin H; Wu CH; Fu HC; Ou YC
    Taiwan J Obstet Gynecol; 2024 Jul; 63(4):471-478. PubMed ID: 39004472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wee1 kinase as a target for cancer therapy.
    Do K; Doroshow JH; Kummar S
    Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775.
    Hauge S; Macurek L; Syljuåsen RG
    Cell Cycle; 2019 Apr; 18(8):834-847. PubMed ID: 30943845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive
    Oza AM; Estevez-Diz M; Grischke EM; Hall M; Marmé F; Provencher D; Uyar D; Weberpals JI; Wenham RM; Laing N; Tracy M; Freshwater T; Lee MA; Liu J; Qiu J; Rose S; Rubin EH; Moore K
    Clin Cancer Res; 2020 Sep; 26(18):4767-4776. PubMed ID: 32611648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.